SM22α inhibits cell proliferation and protects against anticancer drugs and γ-radiation in HepG2 cells: Involvement of metallothioneins  by Kim, Tae Rim et al.
FEBS Letters 583 (2009) 3356–3362journal homepage: www.FEBSLetters .orgSM22a inhibits cell proliferation and protects against anticancer drugs
and c-radiation in HepG2 cells: Involvement of metallothioneins
Tae Rim Kim a,c, Ji Hye Moon a, Hee Min Lee a, Eun Wie Cho b, Sang Gi Paik c, In Gyu Kim a,*
aDepartment of Radiation Biology, Environmental Radiation Research Group, Korea Atomic Energy Research Institute, P.O. Box 105, Yusong, Daejeon 305-600, Republic of Korea
b Systemic Proteomics Research Center, Korea Research Institute of Bioscience and Biotechnology, P.O. Box 115, Yusong, Daejeon 305-333, Republic of Korea
cDepartment of Biology, School of Biosciences and Biotechnology, and the Institute of Biotechnology, Chungnam National University, Daejeon 305-764, Republic of Korea
a r t i c l e i n f o a b s t r a c tArticle history:
Received 26 August 2009
Revised 21 September 2009
Accepted 23 September 2009
Available online 29 September 2009
Edited by Angel Nebrada
Keywords:
SM22a
Luteolin
Cytotoxic drug
IGF-1Rb/Akt
Metallothionein0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.09.040
* Corresponding author. Fax: +82 42 861 9560.
E-mail address: igkim@kaeri.re.kr (I.G. Kim).Smooth muscle protein 22-alpha (SM22a) has been postulated to affect the structure and function of
the actin ﬁlament. In this study, we report on the signiﬁcant induction of SM22a by cytotoxic agents
in HepG2 cells. SM22a-overexpression inhibited the activation of IGF-1Rb/Akt and Erk, consequently
suppressing cell proliferation. On the other hand, SM22a-overexpressing cells became resistant to
apoptotic cell death caused by cytotoxic agents, in which metallothionein (MT) isoforms, especially
MT1G, were signiﬁcantly induced. MT1G-overexpression also conferred cellular resistance, and
SM22a regulated the expression of MT1G at a transcriptional level. This study provides the ﬁrst dem-
onstration of SM22a-induced blockage of cell proliferation and cellular resistance to overcome the
detrimental effects of damaging agents.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Smooth muscle protein 22-alpha (SM22a) is a cytoskeleton-
associated protein that is expressed abundantly in smooth muscle
tissues of normal adult vertebrates [1]. Its expression is one of the
earliest markers of smooth muscle differentiation during embryo-
genesis [2]. Although its physiological role remains uncertain, in-
sights into its potential function are found in studies under its
several different names [3–5]: SM22a, transgelin, WS3-10, and
mouse p27. SM22a is expressed differently in senescent cells and
cancer cells. The SM22a transcript was markedly elevated in
senescent WI-38 diploid ﬁbroblasts [6], ﬁbroblasts from patients
withWerner syndrome [7], and polyamine-deﬁcient leukemia cells
[8]. In cells undergoing long-term single stress (for example,
tert-butyl hydroperoxide), some proteins, including SM22a and
ﬁbronectin, also increased with a subsequent loss of replicative po-
tential. Furthermore, Gourlay et al. [9] reported on a role for the
yeast actin-bundling protein Scp1p, which has homology with
mammalian SM22a, both in cell death and in the promotion of lon-
gevity. The authors showed that decreased actin dynamics by
Scp1p overexpression cause depolarization of the mitochondrial
membrane and an increase in reactive oxygen species production,chemical Societies. Published by Eresulting in cell death. In contrast, in oncogenic transformed cells
such as carcinoma, the expression of SM22a is markedly reduced
[10,11]. These investigations suggested that SM22a might play a
signiﬁcant role in cell differentiation or cellular senescence by sta-
bilizing the cytoskeleton through actin binding.
In the current study, we found that cytotoxic agents such as
anticancer drugs or the oxidant H2O2 signiﬁcantly increased the
cellular levels of SM22a. We consequently investigated the possi-
ble function of SM22a and evaluated for the ﬁrst time both the
anti-proliferative and cytoprotective functions of SM22a in human
hepatocellular carcinoma HepG2 cells. We showed that cytotoxic
agent-induced SM22a functions as a repressor of the IGF-1Rb/Akt
and Erk signaling pathway, which are involved in cell proliferation.
Furthermore, SM22a also plays a protective role against stress-
induced cell damage via the induction of metallothionein (MT),
which confers anticancer drug and c-radiation resistance or toler-
ance to cells.
2. Materials and methods
2.1. Cell culture and chemicals
HepG2 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
(v/v) fetal bovine serum (Hyclone, Logan, UT, USA), 100 U/ml oflsevier B.V. All rights reserved.
Table 1
siRNA target sequences against SM22a.
Primer name Size Sequences (50 ? 30)
siSM22a 673 25mer UGU GAA UUC CCU CUU AUG CUC CUG C
GCA GGA GCA UAA GAG GGA AUU CAC A
siSM22a 709 23mer GCA GGA GGG AAA GCA UGU CAU TT
AUG ACA UGC UUU CCC UCC UGC TT
Table 2
Primer pairs for real-time PCR analysis.
Gene Primers Sequences (50 ? 30)
MT1A Forward CTCGAA ATGGACCCCAACT
Reverse ATATCTTCGAGCAGGGCTGTC
MT1B Forward GCTTGTCTTGGCTCCACA
Reverse AGCAAACCGGTCAGGTAGTTA
MT1E Forward GCTTGTTCGTCTCACTGG TG
Reverse CAGGTTGTGCAGGTTGTTCTA
MT1F Forward AGTCTCTCCTCG GCTTGC
Reverse ACATCTGGGAGA AAGGTTGTC
MT1G Forward CTTCTCGCTTGGGAACTCTA
Reverse AGGGGTCAAGATTGTAGCAAA
MT1J Forward TGAGATCTCCAGCCTTACCG
Reverse TTTGCAGATGCAGCCGTGGG
MT1M Forward TCGAAATGGACCCCA ACTGCT
Reverse TTCCCACATCAGGCACAGCA
MT1Q Forward CAAATGGATCCCAACTGCTCC
Reverse CCCAACATCAGGCACAGCAG
MT1X Forward TCTCCTTGCCTCGAAATGGAC
Reverse GGGCACACTTGGCACAGC
MT M Forward CACCTGATCTCCGAATGGAC
Reverse GCACTTCTCCAATGCCCCTTT
MT2A Forward CCGACTCTAGCCGCCTCTT
Reverse GTGGAAGTCGCGTTCTTTACA
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MT1G-overexpression vectors (SM22a/pcDNA 3.1 and MT1G/
pcDNA 3.1) were constructed as described in the Supplementary
data (S1) and the resultant expression vector was transfected into
the HepG2 cell using Lipofectamine 2000 (Invitrogen), followed by
selection with 500 lg/ml G418 (Calbiochem, San Diego, CA, USA).
The cytotoxic and DNA-damaging reagents luteolin, methyl meth-
anesulfonate (MMS), cis-platinum(II)-diamine dichloride, menadi-
one and H2O2 were purchased from Sigma–Aldrich Co. (St. Louis,
MO, USA), and cells were treated as indicated. For c-irradiation,
cells were cultured in T25 ﬂask (1  106 cells/ﬂask) and after
24 h irradiated with a single exposure to a dose of 10 Gy (60Co c-
ray source; dose rate, 1 Gy/min). The cells were then cultured for
the indicated time periods.
2.2. Measurement of cell viability and cell death
Cell viability was measured by a trypan blue exclusion assay or
crystal violet staining. Cell death was measured by subG1/G0
phase analysis of propidium iodide stained cells, as described pre-
viously [8].
2.3. Western blot analysis
Protein extract preparation and Western blotting were per-
formed, as previously described [12], using probes with primary
antibodies speciﬁc for human SM22a (Abcam, London, UK), phos-
pho-Ser473 Akt, Akt, phospho-insulin-like growth factor 1 receptor
(IGF-1R) b(Tyr1131)/insulin receptor b(Tyr1146), IGF-1R b(111A9)
(Cell Signaling Technology, Danvers, MA, USA), and the corre-
sponding secondary antibodies (anti-mouse IgG horseradish per-
oxidase (HRP)-linked antibody, anti-rabbit IgG HRP-linked
antibody [Cell Signaling Technology], and anti-goat IgG HRP-linked
antibody [Sigma–Aldrich]). Protein concentration was determined
by the Lowry method [13].
2.4. RT-PCR analysis
Total RNA was isolated from the cells with easy-BLUETM Reagent
(iNtRON Biotechnology, Sungnam, Korea) according to the manu-
facturer’s instructions. One microgram of the total RNA was used
for synthesis of the RT-PCR product in a 20 ll reaction mixture
containing ONE-STEP RT-PCR PreMix (iNtRON Biotechnology) and
primers (SM22a, forward: 50-TTGGATCCGACATGGCCAACAAG-30;
reverse: 50-GCCCTAAGCTTTCTAACTGATGATCT-30; b-actin, for-
ward: 50-CATCCTCACCCTGAAGTACCC-30; reverse: 50-AGCCTGGAT-
AGCAACGTACATG-30). PCR was carried out as follows: 45 C for
30 min and 94 C for 5 min; 43 cycles at 94 C for 1 min, 59 C
for 45 s, and 72 C for 45 s. The PCR products were separated on
a 1% agarose gel and visualized by ethidium bromide staining.
2.5. Senescence-associated b-galactosidase (SA-b-Gal) activity
staining
SA-b-Gal activity staining was performed by using bromo-4-
chloro-3-indolyl-b-D-galactosidase, as described previously [14].
The stained cells were observed with an optical microscope (Leica
Microsystems, Mannheim, Germany) and portions of positively
stained cells were statistically analyzed.
2.6. siRNA targeting of SM22a
Cells were transfected with either StealthTM RNA targeting
SM22a (Invitrogen; primer sequences in Table 1), or StealthTM
RNAi negative control Medium GC (Invitrogen) at a concentration
of 100 nM using the LipofectamineTM RNAi MAX reagent (Invitro-gen). The cells were incubated for 72 h post-transfection, after
which SM22a expression was determined.
2.7. Real-time PCR analysis
Total RNA was reverse-transcribed with the use of M-MLV Re-
verse Transcriptase (Promega, Madison, WI, USA), according to
the manufacturer’s speciﬁcations. Quantitative real-time PCR was
performed with a Rotor Gene 2000 (Cobett Research, Sydney, Aus-
tralia) and a SYBR Green I reaction (Qiagen, Hilden, Germany) with
appropriate primer pairs. Primer pairs of MT isoforms for real-time
PCR are listed in Table 2.
2.8. Methylation-speciﬁc PCR assay
Bisulﬁte-modiﬁed genomic DNA was prepared with the EZ DNA
Methylation-Gold kit (Zymo Research, Orange, CA, USA), according
to the manufacturer’s instructions. The DNAmethylation pattern in
the CpG islands of the genes was determined by subsequent PCR
with primer pairs speciﬁc to methylated (M primer pair) or unme-
thylated (U primer pair) DNA sequences. Each primer was designed
with MethPrimer [15], and the primer sequence is listed in Table 3.
PCR was carried out as described by the manufacturer. Samples
were afterwards run on a 2% agarose gel and the presence or ab-
sence of PCR products was analyzed.
2.9. Luciferase assay of MT1G promoter activity
Luciferase-reporter plasmids of the MT1G promoter region
were constructed as described in the Supplementary data S2. For
Table 3
PCR primers for DNA methylation analysis of metallothionein isoforms.
Gene Primers Sequences (50 ? 30)
MT1F M primer-left GTTTGAGCGGATTTTAAAGGGAC
M primer-right ATATACAACAAAAAAACCGAACGCA
U primer-left GTTTGAGTGGATTTTAAAGGGATGG
U primer-right ATATACAACAAAAAAACCAAACACA
MT1G M primer-left GTAGGGTGAGAGAAGTCGTATACGG
M primer-right AAAATCCCTTAAACGCAACTAAACG
U primer-left GGTAGGGTGAGAGAAGTTGTATATGG
U primer-right AATCCCTTAAACACAACTAAACACA
MT1J M primer-left TCGTTGGTTATCGTACGTTTTTCGT
M primer-right ACTAAACCTATCCCGAAATCCCGAT
U primer-left TTTGTTGGTTATTGTATGTTTTTTGT
U primer-right ACTAAACCTATCCCAAAATCCCAAT
MT1M M primer-left GAGGAGTTAGTTCGAGGGATCGC
M primer-right AAACGAATCGTATACAAAACACCCG
U primer-left GGAGGAGTTAGTTTGAGGGATTGTG
U primer-right ACAAATCATATACAAAACACCCACC
MT1X M primer-left GTTGTTGTATTCGGTTTAGGATCGC
M primer-right AAACCGACGACTCTCTTTATAATCCG
U primer-left TTGTTGTATTTGGTTTAGGATTGTGG
U primer-right CAAAAACCAACAACTCTCTTTATAATCCAA
MT2A M primer-left TTCGTTTTTATTCGCGCGTTAAC
M primer-right GAATACTAAATACCCACGCCGTACG
U primer-left TTTGTTTTTATTTGTGTGTTAATGG
U primer-right ACCAAATACTAAATACCCACACCATACACC
MT 3 M primer-left TTTAAGCGTATAAACGGAAAGAGCG
M primer-right TTATAACCTCGAACGAAAACGCG
U primer-left GAGTTTAAGTGTATAAATGGAAAGAGTGG
U primer-right TTATAACCTCAAACAAAAACACACA
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luciferase-reporter vectors using Lipofectamine 2000 (Invitrogen).
After incubation for 48 h, the cells were harvested and lysed with
luciferase lysis buffer, and the luciferase activity of each sample
was measured with a luciferase assay kit (Promega). All experi-
ments were carried out in triplicate and repeated at least three
times.
3. Results
3.1. SM22a-overexpression inhibits cell proliferation and protects cells
against cytotoxic and DNA-damaging agents
In the course of searching for genes or proteins that protect cells
against anticancer drugs or oxidants, we found that the treatment
of luteolin, menadione, or H2O2 in HepG2 cells increases the
expression of SM22a on a dose-dependent basis (Fig. 1A). For the
characterization of the biological role of SM22a, SM22a-over-
expressing HepG2 cell lines (SM22a(+)) were constructed
(Fig. 1B). SM22a-overexpressing stable cell lines were signiﬁcantly
different from vector-transfected control cells with regard to their
cell proliferation rate, in which SM22a-overexpression suppressed
the cell growth to about half of that of the control cells (Fig. 1C).
SM22a has been known as a typical marker of senescence [6],
which would cause the reduction of cell number. However,
SM22a-overexpression in HepG2 cells did not lead cells to a senes-
cence state, according to the results of SA-b-gal staining of these
cells (Fig. 1D). This result implies that the increment of SM22a
may not be the inducer of senescence but can cause growth inhibi-
tion in tumor cells. Next, SM22a-overexpressing and control vec-
tor-transfected cells were challenged with various cytotoxic
agents (luteolin, c-radiation, menadione, cisplatin, and MMS),
and then apoptotic cell death was measured. Luteolin treatment
on control vector-transfected HepG2 cells for 48 h at 0.5 mM
caused extensive cell death (about 96%), whereas SM22a-over-expressing cells were substantially more resistant to luteolin than
vector-transfected cells (Fig. 1E; sFig. 1A). When the cells were ex-
posed to a single dose of c-radiation (10 Gy), the radiation-induced
cell death of vector-transfected control cells was usually about 55%
at 24 h after radiation. However, the cell death of SM22a(+) cells
was markedly diminished. Similar results were also obtained for
other cytotoxic agents, as shown in Fig. 1E, and cell proliferation
assay using MTT also showed the same results (sFig. 1B). Also,
these results were conﬁrmed in two independent SM22a-over-
expressing clones (SL4 and SL6; sFig. 1C and D). These results
strongly indicate that SM22a-overexpression may also be closely
related to protection against cytotoxic agents. In reverse, SM22a-
suppression using siRNA (Fig. 1B) sensitized the cells to a variety
of damaging agents and anticancer drugs (Fig. 1F; sFig. 1E).
3.2. SM22a functions as a suppressor of the IGF-1Rb/Akt and Erk
pathways and an inducer of cellular MT isoforms
Attempts were made to understand how SM22a inhibits cell
proliferation and protects cells against a variety of agents. The
IGF-1Rb/Akt pathway has been known to function as a hub in the
cell signaling pathways that control cell growth and survival. Akt
activation promotes cell proliferation and angiogenesis. Akt activa-
tion also promotes resistance to chemo- and radiotherapy. There-
fore, it was investigated whether SM22a is related to Akt
activation with regard to cell proliferation and resistance to cyto-
toxic drugs. As shown in Fig. 2A, SM22a-overexpression did not in-
duce Akt activation (phosphorylation of Akt). SM22a-
overexpression diminished the basal level of activated Akt. More-
over, IGF-1Rb activation, which is the upstream target of Akt,
was signiﬁcantly diminished. SM22a-overexpression also inhib-
ited Erk activation related to cell growth and proliferation. These
ﬁndings indicate that SM22a functions as a suppressor of activa-
tion of IGF-1Rb/Akt and Erk pathways, which may cause the inhi-
bition of cell proliferation. These results were also showed in
luteolin-treated HepG2 cells, suggesting that SM22a may be in-
volved in functions related to luteolin-induced cell growth inhibi-
tion (Fig. 2B). Because SM22a-overexpression did not induce
activation of the IGF-1Rb/AKT pathway, which has been known
to be the key signaling pathway conferring chemo-resistance to
cells, we performed a DNA array experiment on SM22a-over-
expressing cells to screen the changes of possible downstream
gene expression conferred by SM22a-overexpression that is re-
lated to cell resistance or tolerance (data not shown). Gene expres-
sion analysis showed that the MT isoforms, which have been
reported to be related to cellular resistance against cytotoxicity
[16], were greatly upregulated in SM22a-overexpressing cells.
We also assessed the induction of MT isoforms in SM22a-over-
expressing HepG2 cells via a real-time RT-PCR analysis (Fig. 3A).
Here we showed that various kinds of MT isoforms were induced
and expressed differentially in SM22a-overexpressing cells. MT
isoforms were also upregulated in luteolin-treated HepG2 cells,
which had shown the induction of SM22a (Fig. 3B). This means
that luteolin-induced SM22a may be involved in the induction of
MT isoforms. Among MT isoforms, MT1G and MT1F were ex-
pressed in strikingly high levels. In reverse, SM22a-suppression
decreased MT1G expression (Fig. 3C). In addition to MT isoforms,
the DNA array experiment showed the cellular level of wild-type
p53 was signiﬁcantly increased in SM22a-overexpressing cells,
which was also conﬁrmed by Western blot analysis (Fig. 2A).
3.3. MT1G protects against a number of cytotoxic agents and is
controlled at a transcriptional level
To investigate the involvement of MT isoforms induced by
SM22a to cellular resistance against cytotoxicity, an MT1G-overex-
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Fig. 2. SM22a-overexpression suppressed the activation of IGF-1Rb/Akt and Erk
signaling pathways, and induced the expression of various metallothionein (MT)
isoforms. (A) Western blot analysis of the activation of IGF-1Rb/AKT and ERK, and
p53 protein in SM22a-overexpressing cells. Twenty micrograms of total cell lysates
was loaded to each lane. (B) Western blot analysis of the activation of IGF-1Rb/AKT
in luteolin-treated HepG2 cells. Twenty micrograms of total cell lysate was loaded
to each lane.
Fig. 1. SM22a-overexpression reduced the cytotoxicity caused by drugs or irradiation. (A) Western blot analysis of SM22a after treatment of luteolin, menadione, or H2O2 on
HepG2 cells (2  106 cells/5 ml) at indicated concentrations for 24 h. Twenty micrograms of total cell lysates was loaded to each lane. (B) RT-PCR andWestern blot analysis of
SM22a in SM22a/pcDNA3.1 stably transfected cells (SM22a(+)) and siSM22a-transfected cells (siSM22a). NC: non-transfected cells; VC: empty vector (pcDNA3.1)-
transfected cells; siControl: control siRNA-transfected cells. The amounts of total cell lysates used for Western blot analysis of SM22awere 20 lg (SM22a(+) and control cells)
or 80 lg (siSM22a and siControl cells). (C) Cell growth curves of SM22a-overexpressing cells. The inoculated cell number was 1  105 cells/ml. (D) SA-b-Gal staining of
SM22a-overexpressing cells. (E) Cell death caused by various cytotoxic drugs or agents in SM22a-overexpressing cells. Cytotoxic drugs or agents were treated on the cells
(1  106 cells/2 ml), and the subG0/G1 phase of these cells was analyzed. An MTT assay was performed also (Supplementary data; sFig. 2B). (F) Cell death caused by various
cytotoxic drugs in cells with SM22a-suppression using siRNA (siSM22a 673).
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pressed cells were exposed to cytotoxic agents such as menadione,cell death was signiﬁcantly reduced, as in SM22a-overexpressing
cells (Fig. 4B; sFig. 2). Therefore, attempts were made to under-
stand the molecular mechanism underlying the induction of the
MT isoforms by SM22a. Previous studies suggested that downreg-
ulation of MT in hepatic tumors may be related to hypermethyla-
tion of the MT promoter or mutation of other genes such as the
p53 tumor suppressor gene [17–19]. Therefore, the cellular effect
of SM22a on the methylation and demethylation of MT family
genes was investigated ﬁrst. But, as shown in Fig. 4C, SM22a-over-
expression did not affect the demethylation in the methylated pro-
moter region of MT genes. The demethylation pattern of speciﬁc
MT genes did not coincide with the induction proﬁle obtained by
a real-time PCR. We next examined whether SM22a regulates
the MT isozymes at a transcriptional level. As measured by a repor-
ter assay including luciferase, SM22a-overexpression greatly in-
creased the promoter activity of MT1G (Fig. 4D). Although the
underlying full signal pathway is still uncertain, this ﬁnding im-
plies that SM22a regulates MT1G at a transcriptional level and that
its overexpression affects induction of the MT isoform genes, thus
conferring cell resistance or tolerance by preventing DNA damage.
Until now, the gene or protein that could inﬂuence MT expression
in human tumors has not yet been understood. In this aspect,
SM22a is the ﬁrst protein shown to regulate gene expression of
the MT isoforms directly or indirectly.
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Fig. 4. MT1G protects cells from various cytotoxic agents, and its expression is affected by SM22a. (A) RT-PCR and real-time PCR analysis of MT1G-overexpressed cells. (B)
Cell death caused by various cytotoxic drugs or agents in the MT1G-overexpressed cells (1  106 cells/2 ml) and subG0/G1 phase was analyzed. (C) Methylation-speciﬁc PCR
(MSP) assay for metallothionein (MT) isoforms (M: methylated DNA-speciﬁc primer; U: unmethylated DNA-speciﬁc primer). (D) Luciferase reporter assay for the
measurement of MT1G promoter activity in SM22a-overexpressing cells.
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SM22a, a dominant protein in smooth muscle cells, has been
reported to be abnormally down-regulated in many solid tumors,
which makes it an early and sensitive marker for the onset of
transformation. The physiological role of SM22a is still unclear,
but recent studies show that SM22a may play a pivotal role in
agonist-induced vascular smooth muscle contractility [20].
Another tangible function of this protein is that SM22a mayfunction as a regulator of Erk signaling in cancer cells. Nair
et al. [21] showed that SM22a functions as a novel repressor
of metallomatrix protease (MMP-9) expression in HT-1080 ﬁbro-
sarcoma cells via transient Erk activation, which made them sug-
gest that a low level of SM22a in cancer cells may partly
account for the elevated MMP-9 expression evident in these
tumors.
In this study, we reported about the function of SM22a as a
negative regulator of the IGF-1Rb/Akt and Erk signaling pathway
T.R. Kim et al. / FEBS Letters 583 (2009) 3356–3362 3361as well as a transcriptional activator of MT isoforms in HepG2
cells. IGF-1R is a transmembrane tyrosine kinase that is fre-
quently overexpressed in tumor cells and mediates cell growth
and proliferation or protection of cell death. Previous studies
have shown that IGF-1R blockage inhibits HepG2 cell prolifera-
tion and sensitizes cells to cytotoxic drugs [22]. Therefore, we
anticipated that SM22a-induced resistance is caused by the acti-
vation of the IGF-1Rb/Akt signal pathway. However, SM22a sup-
pressed the IGF-1Rb/Akt activation in HepG2 cells, which
implicates that other factors might be related to SM22a-induced
resistance. The inhibition of IGF-1Rb by SM22a seems to be
more related to its function as a repressor of cell growth and
proliferation. Erk inactivation also supports the anti-proliferative
property of SM22a. On the other hand, SM22a positively regu-
lates the expression of MT isoforms, which may confer cellular
resistance or tolerance to anticancer drugs and agents. MT,
which belongs to a group of ubiquitous low-molecular-mass cys-
teine-rich metal-binding proteins, is encoded by a family of
genes containing at least 10 functional isoforms in human cells
[17,23]. A number of studies have shown that MT increased in
various human tumors including cancers of the lung, prostate,
and ovary. It is well known that induction of these MT proteins
is associated with cell protection against DNA damage and cell
survival [16]. Luteolin has been well known to inhibit cell prolif-
eration and confer resistance to various cells [24,25]. In this
study, we ﬁrst showed that luteolin treatment in HepG2 cells in-
duced cellular SM22a and MT isoforms, and that these proteins
may possess both an anti-proliferative property and a cytopro-
tective function against cell damage.
Recent studies have indicated a strong relationship between MT
and p53, a critical component in repair and apoptotic cell death. It
has been suggested that the metal binding properties of MT can af-
fect the activity of p53, a zinc-dependent protein. The zinc ions are
essential for the maintenance of wild-type conformation and the
stability of the p53 protein that activates proapoptotic signals
when DNA damage is severe [26–28]. Some in vitro studies have
shown that MT functions as metal chelator, sequesters zinc from
p53, and thereby mediates a ‘p53 null state’ [19,26–28]. In
SM22a-overexpressing cells, the wild-type p53 protein level was
elevated, but apoptosis-mediated cell death was not induced. It
may indicate that the increased p53 proteins were not in an active
state. Excess MT isozymes, which had been induced by SM22a,
might inhibit p53 activation by their metal chelating abilities,
hereby preventing apoptotic cell death in spite of up-regulation
of the p53 level. This research suggests that the cytotoxic agent-in-
duced SM22a/MT isozyme induction/p53 inactivation pathway is
very important in the effort to elucidate biological functions of
SM22a, such as resistance or tolerance of tumor cells to chemo-
therapy and stress. This information could provide insights into
increasing the sensitization effect of cell death induced by antican-
cer drugs.
Resistance or tolerance to chemotherapy and radiotherapy is a
major obstacle in treating malignant cancer. In the case of
exposure to cytotoxic drugs including luteolin and menadione,
the drug dosage determines whether cells die or adapt to the
drugs and survive. A large portion of cells progress to death; how-
ever, some cells possess the ability to overcome the detrimental
effects of damaging agents, and selection for resistance to drug-
induced cell death occurs. Based on our studies, SM22a may be
able to mediate the activation of genes essential for cell survival
against cytotoxic drugs and thus assist selection for resistance or
tolerance.
In conclusion, SM22a is a protein newly identiﬁed as playing a
crucial role in blocking cell proliferation and in resistance or toler-
ance. This study suggests novel mechanisms for resistance or toler-
ance to damaging agents.Acknowledgement
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